Brief: Coeptis Therapeutics To Acquire Allogeneic Immuno-Oncology Nk Platform In Phase 1 Clinical Trials From Deverra Therapeutics
18/04/2023 12:36
April 18 (Reuters) - Coeptis Therapeutics Holdings Inc
COEP.O :
* COEPTIS THERAPEUTICS SIGNS AGREEMENT TO ACQUIRE ALLOGENEIC
IMMUNO-ONCOLOGY NK PLATFORM IN PHASE 1 CLINICAL TRIALS FROM
DEVERRA THERAPEUTICS
* COEPTIS THERAPEUTICS HOLDINGS INC - CLINICAL DATA FROM AML
CLINICAL TRIAL EXPECTED DURING 2H 2023
* COEPTIS THERAPEUTICS HOLDINGS INC - HAS ENTERED INTO A
BINDING
TERM SHEET WITH DEVERRA THERAPEUTICS, INC
Source text for Eikon: ID:nPn70pN0Da
Further company coverage: COEP.O
Recent news on Z Squared (Delaware)
See all newsBrief: Z Squared Inc. Signs Definitive Agreement To Acquire 100% Of Paradox Data And Its Union County Campus
Brief: Z Squared, Inc. To Acquire Majority Interest In Paradox Data And Its Union County Campus, A Next-Generation Data Center Development Targeting Up To 150 MW Of Firm Power
Brief: Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement To Support Ai Infrastructure Buildout
Brief: Z Squared Appoints Jon Najarian, Pete Najarian, Marc Lopresti And Jay Zapata To Newly Formed Advisory Board
Brief: Z Squared Announces Executive Leadership Appointments To Advance Ai Infrastructure Strategy